17 October 2019

New biomedical innovations offer the promise of personalised medicine and health. Getting there requires huge amounts of sensitive personal health and care data.

The PhD thesis of Martin Boeckhout (Promotors prof. dr. A.L. Bredenoord and prof. dr. G.A. Zielhuis, defended on  June 6th, 2019) investigates the ethical challenges for health research infrastructures that facilitate the collection, management and use of such data.
 
Contemporary research data is usually collected with the expectation of systematic reuse. This is a positive development, but responsible data stewardship also requires quality control, privacy protection, and policies for sustained public availability of health research data. Ethics review is an important means to stimulate and provide oversight over such measures. For Dutch biobanks facilitating research with human tissue, this is now standard practice, but the shape of such review still varies considerably.

The systematic integration of data-driven research into health care could bring along additional risks to patients and patient care. However, research and care also stand to benefit from such integration, particularly for symptoms, diseases and treatments about which little is known. This calls for extensive involvement of patients and enhanced attention to the professional responsibility of health researchers. Expanding the scope of research settings calls for further reflection on the impact of research.
 
More and more patients and citizens contribute personal health data and human tissue to health research. This calls for measures aimed at privacy protection, personal data control, and active participant involvement in shaping research. In contributing to such goals, ethics parallel research can also help contribute to a responsible embedding of health research infrastructure in health care and society.

 
  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud Biobank

Related news items


Dutch-Nordic Alliance for Precision Cancer Medicine launched

26 November 2021

The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.

read more

New Automated PBMC isolation method introduced in LMI.

21 September 2021

The Radboud Biobank (RB) and the laboratory of Medical Immunology (LMI) are making plans to replace the density gradient centrifugation method with a new automated PBMC isolation method, the AutoMACS Pro Separator.

read more

Health-RI, geared up to accelerate

21 September 2021

The Dutch cabinet has selected Health-RI's National Growth Fund proposal for a national health data infrastructure. On 5 October, the kick-off will take place during a live meeting in Jaarbeurs Media Plaza in Utrecht.

read more

SUNRISE-CRC sub-biobank

21 September 2021

The main purpose of SUNRISE-CRC is to determine whether treatment with a high dose of sunitinib provides a better chance of survival and slows the progression of (colo)rectal cancer (CRC) more than standard treatment with TAS-102.

read more

PRECISE sub-biobank

21 September 2021

The aim of the PRECISE biobank is to develop the first, smart multi-modal liquid biopsy test service for the prediction of immune checkpoint inhibitor response in urothelial cancer (UC) patients – the PRECISE IVD.

read more

Lysine Metabolism sub-biobank

21 September 2021

Hereditary metabolic disorders form a large group of more than 1,400 rare disorders in which an error in the DNA causes abnormalities in the process in which proteins, fats and carbohydrates are converted into smaller building materials and energy.

read more